IDEXX Laboratoriesvs.Natera
IDXX vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Natera is about 1.4× larger than IDEXX Laboratories by market cap; year to date, Natera leads (+72.7% vs −25.1%).
Side by side
| IDXX | NTRA | |
|---|---|---|
| Market cap | $40.1B | $55.6B |
| Price | $513.14 | $390.79 |
| Today | +1.3% | −1.2% |
| Return YTD | −25.1% | +72.7% |
| Return 1Y | −19.2% | +134.7% |
| Since June 26, 2026 | −7.0% | +49.2% |
| P/E | 35.2 | — |
| P/S | 8.8 | 20.5 |
| P/B | 24.9 | 30.5 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
IDEXX LaboratoriesIDXX
Vets are the customers. IDEXX sells the analysers that sit in the clinic, runs the reference laboratories that handle samples sent out, and writes the software the practice runs on.
Full IDXX profile →NateraNTRA
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Full NTRA profile →More IDXX & NTRA comparisons
Other head-to-heads in the Diagnostics segment.